| Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.J Int Assoc Provid AIDS Care | Pooled analysis | 2026 |
| Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.Obes Res Clin Pract | Pooled analysis | 2026 |
| Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.J Infect Dis | Random groups | 2025 |
| Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.AIDS | Random groups | 2024 |
| Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.Clin Infect Dis | Random groups | 2021 |
| Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.Clin Infect Dis | Random groups | 2021 |
| Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI Insight | Random groups | 2020 |
| Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.Lancet HIV | Random groups | 2019 |
| The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.J Frailty Aging | Random groups | 2019 |
| Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth Horm IGF Res | Random groups | 2017 |
| Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.PLoS One | Random groups | 2017 |
| Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.PLoS One | Random groups | 2015 |
| Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.Clin Pharmacokinet | Random groups | 2015 |
| The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.J Clin Endocrinol Metab | Random groups | 2014 |
| Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.JAMA Neurol | Random groups | 2013 |
| Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.J Clin Endocrinol Metab | Random groups | 2012 |
| Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Arch Neurol | Random groups | 2012 |
| Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clin Infect Dis | Random groups | 2012 |
| Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.AIDS | Random groups | 2011 |
| Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS | Random groups | 2008 |
| Metabolic effects of a growth hormone-releasing factor in patients with HIV.N Engl J Med | Random groups | 2007 |
| Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.J Pharmacokinet Pharmacodyn | No random groups | 2015 |
| Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.Growth Horm IGF Res | No random groups | 2011 |
| Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.Clin Infect Dis | Case reports | 2026 |
| Approach to the Patient With Lipodystrophy.J Clin Endocrinol Metab | Case reports | 2022 |
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.Sex Med Rev | Review of studies | 2026 |
| The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.JBJS Rev | Review of studies | 2026 |
| Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci | Review of studies | 2026 |
| Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.J Clin Med | Review of studies | 2026 |
| Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev | Review of studies | 2026 |
| Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med | Review of studies | 2026 |
| Metabolic dysfunction-associated steatotic liver disease in people with HIV.Curr Opin HIV AIDS | Review of studies | 2025 |
| CROI 2024: Neuropsychiatric Complications in People With HIV.Top Antivir Med | Review of studies | 2024 |
| Causes and outcomes of hepatic fibrosis in persons living with HIV.Curr Opin HIV AIDS | Review of studies | 2022 |
| Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.Drug Des Devel Ther | Review of studies | 2021 |
| Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC Infect Dis | Review of studies | 2017 |
| Growth hormone deficiency and human immunodeficiency virus.Best Pract Res Clin Endocrinol Metab | Review of studies | 2017 |
| Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury.Expert Opin Ther Targets | Review of studies | 2016 |
| Growth hormone in the aging male.Best Pract Res Clin Endocrinol Metab | Review of studies | 2013 |
| Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.Rev Endocr Metab Disord | Review of studies | 2013 |
| How to diagnose a lipodystrophy syndrome.Ann Endocrinol (Paris) | Review of studies | 2012 |
| Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.Ann Pharmacother | Review of studies | 2012 |
| Spotlight on tesamorelin in HIV-associated lipodystrophy.BioDrugs | Review of studies | 2011 |
| Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.HIV Med | Review of studies | 2011 |
| Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs | Review of studies | 2011 |
| Pathogenesis and treatment of HIV lipohypertrophy.Curr Opin Infect Dis | Review of studies | 2011 |
| Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.Curr Opin Investig Drugs | Review of studies | 2010 |
| Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.AIDS Rev | Review of studies | 2010 |
| Tesamorelin, a human growth hormone releasing factor analogue.Expert Opin Investig Drugs | Review of studies | 2009 |
| Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.Curr Opin Investig Drugs | Review of studies | 2006 |
| Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.Braz J Med Biol Res | In animals | 2026 |
| Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug Test Anal | In a lab dish | 2021 |
| The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci | Other paper | 2026 |
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.BMJ Open | Other paper | 2026 |
| Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.J Pharm Biomed Anal | Other paper | 2026 |
| Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.Cureus | Other paper | 2025 |
| Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome.PLoS One | Other paper | 2024 |
| Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.J Mass Spectrom | Other paper | 2024 |
| Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.Anal Biochem | Other paper | 2023 |
| Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.J Clin Transl Sci | Other paper | 2023 |
| Probing for peptidic drugs (2-10 kDa) in doping control blood samples.Anal Sci Adv | Other paper | 2022 |
| An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.J Pharm Biomed Anal | Other paper | 2022 |
| Tesamorelin improves fat quality independent of changes in fat quantity.AIDS | Other paper | 2021 |
| Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.Sci Rep | Other paper | 2021 |
| Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.J Chromatogr A | Other paper | 2020 |
| Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.J Am Chem Soc | Other paper | 2020 |
| Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV.Nutr Diabetes | Other paper | 2019 |
| Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.AIDS | Other paper | 2017 |
| Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.Anal Bioanal Chem | Other paper | 2016 |
| Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.Drug Test Anal | Other paper | 2015 |
| Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers.Clin Pharmacol Drug Dev | Other paper | 2013 |
| Neuroendocrinology: Tesamorelin can improve cognitive function.Nat Rev Endocrinol | Other paper | 2012 |
| Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.Indian J Endocrinol Metab | Other paper | 2012 |
| Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.Drugs Today (Barc) | Other paper | 2011 |
| Tesamorelin: A hope for ART-induced lipodystrophy.J Pharm Bioallied Sci | Other paper | 2011 |
| Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy.Expert Rev Endocrinol Metab | Other paper | 2011 |
| Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.HIV AIDS (Auckl) | Other paper | 2011 |
| Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.J Clin Endocrinol Metab | Other paper | 2011 |
| Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.J Clin Endocrinol Metab | Other paper | 2010 |
| Tesamorelin update.BETA | Other paper | 2010 |
| The next generation of human growth hormone. How Serostim and tesamorelin measure up.Posit Aware | Other paper | 2008 |
| Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.Posit Aware | Other paper | 2008 |
| Side effects and complications. Tesamorelin--results from Phase III.TreatmentUpdate | Other paper | 2007 |
| Side effects and complications. Clinical trials of tesamorelin in Canada.TreatmentUpdate | Other paper | 2007 |